Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App




Predicting Heart Problems After Liver Transplant

By HospiMedica staff writers
Posted on 21 Mar 2006
A study comparing the scores of three global cardiovascular disease risk-stratification algorithms in liver transplant patients found that two of the methods were better than the third.

Researchers at Virchow-Klinikum (Berlin, Germany) retrospectively studied 303 patients who had received a liver transplant between 1988 and 1994. More...
They gathered clinical and demographic data at six months post-transplant and used it to calculate three established cardiovascular risk scores: the Framingham risk score (FRS), the German prospective cardiovascular Münster study (PROCAM), and the European systematic coronary risk evaluation project (SCORE), all of which predict the 10-year-risk of coronary or cardiovascular events or fatalities.

The researchers, led by Dr. Olaf Guckelberger of the department of general, visceral, and
transplantation surgery at the clinic, then compared the actual incidence of cardiovascular events, such as myocardial infarction (MI) and coronary heart disease over 10 years post-transplant to better understand the predictive power of each score. They found that PROCAM and SCORE provided excellent measures to discriminate between patients at high or low risk for coronary events, but that the Framingham risk score did not identify high-risk liver transplant recipients as accurately. The findings were published in the March 2006 issue of Liver Transplantation.

Patients who receive liver transplants often have an increased prevalence of cardiovascular risk factors, and cardiovascular events are a major source of their morbidity and mortality. Due to excellent long-term survival, there is an increasing emphasis on identifying transplant recipients at risk for immunosuppression-related late complications.



Related Links:
Virchow-Klinikum

Gold Member
POC Blood Gas Analyzer
Stat Profile Prime Plus
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Ultrasound Needle Guidance System
SonoSite L25
Silver Member
X-Ray QA Device
Accu-Gold+ Touch Pro
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: The collaboration will integrate Masimo’s innovations into Philips’ multi-parameter monitoring platforms (Photo courtesy of Royal Philips)

Philips and Masimo Partner to Advance Patient Monitoring Measurement Technologies

Royal Philips (Amsterdam, Netherlands) and Masimo (Irvine, California, USA) have renewed their multi-year strategic collaboration, combining Philips’ expertise in patient monitoring with Masimo’s noninvasive... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.